装有ZnPP的纳米颗粒可以改善肥胖期间的葡萄糖平衡和慢性炎症
Wanbao Yang1, Meenakshi Arora2,3, Hye Won Han1
1Department of Nutrition, College of Agriculture and Life Sciences, Texas A&M University, College Station, Texas, USA.
British journal of pharmacology
|April 28, 2024
概括
纳米颗粒有效地释放了血氧酶-1 (HO-1) 抑制剂,原氨酸IX (ZnPP),改善了葡萄糖平衡,并减少了肥胖小鼠的炎症. 这种纳米粒子配方为2型糖尿病 (T2DM) 提供了一个有前途的治疗策略.
科学领域:
- 代谢性疾病研究研究.
- 纳米医学应用程序
- 免疫学和炎症的研究
背景情况:
- 慢性炎症是2型糖尿病 (T2DM) 发展的关键因素.
- 血液氧化酶-1 (HO-1) 在代谢压力中起着促炎作用.
- 现有的HO-1抑制剂由于溶解性差而面临生物可用性挑战.
研究的目的:
- 将HO-1抑制剂,原氨酸IX (ZnPP) 封装成纳米粒子.
- 研究ZnPP装载纳米颗粒 (Nano-ZnPP) 在调节葡萄糖平衡和肥胖症慢性炎症中的治疗潜力.
- 为了比较纳米-ZnPP与传统的DMSO溶解ZnPP的疗效.
主要方法:
- 饮食诱导的肥胖小鼠被用DMSO-ZnPP或Nano-ZnPP治疗了六周.
- 进行葡萄糖和胰岛素耐受性测试以评估代谢功能.
- 在肝脏和脂肪组织中进行基因表达分析,并对系统性炎症进行流动细胞计.
主要成果:
- 纳米-ZnPP在细胞和小鼠中证明了ZnPP的增强传递效率.
- 在肥胖小鼠中,纳米-ZnPP显著降低了脂肪,改善了胰岛素敏感性和增强了葡萄糖耐受性.
- 纳米-ZnPP有效地减轻了局部和全身炎症,抑制了肝脏的葡萄糖和TNF信号传递,并调节了脂肪组织通路.
结论:
- 装有ZnPP的纳米粒子代表了对T2DM的有前途的治疗方法.
- 与DMSO-ZnPP相比,纳米-ZnPP在改善葡萄糖代谢和减少炎症方面表现出更高的疗效.
- 这种纳米医学策略克服了HO-1抑制剂在T2DM治疗中的生物可用性限制.
相关概念视频
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Regulation of Food Intake
225
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
225
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154


